Cancer immunotherapy: Silencing intracellular negative immune regulators of dendritic cells

Yao Hua Liu, I. Jeng Yeh, Ming-Derg Lai, Kuan Ting Liu, Po Lin Kuo, Meng Chi Yen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be a strategy to silence specific intracellular targets in DCs. This review provides an overview of the known negative immune regulators of DCs. Moreover, a combination of shRNA/siRNA and DC vaccines, DNA vaccines in animal models, and clinical trials are also discussed.

Original languageEnglish
Article number108
JournalCancers
Volume11
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Immunotherapy
Dendritic Cells
Small Interfering RNA
Neoplasms
DNA Vaccines
Tumor Microenvironment
Adaptive Immunity
Regulatory T-Lymphocytes
Cell Differentiation
Vaccines
Animal Models
Clinical Trials
T-Lymphocytes
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Liu, Yao Hua ; Yeh, I. Jeng ; Lai, Ming-Derg ; Liu, Kuan Ting ; Kuo, Po Lin ; Yen, Meng Chi. / Cancer immunotherapy : Silencing intracellular negative immune regulators of dendritic cells. In: Cancers. 2019 ; Vol. 11, No. 1.
@article{2b1e7f7cdb7245fc91171aeb6281333c,
title = "Cancer immunotherapy: Silencing intracellular negative immune regulators of dendritic cells",
abstract = "Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be a strategy to silence specific intracellular targets in DCs. This review provides an overview of the known negative immune regulators of DCs. Moreover, a combination of shRNA/siRNA and DC vaccines, DNA vaccines in animal models, and clinical trials are also discussed.",
author = "Liu, {Yao Hua} and Yeh, {I. Jeng} and Ming-Derg Lai and Liu, {Kuan Ting} and Kuo, {Po Lin} and Yen, {Meng Chi}",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/cancers11010108",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

Cancer immunotherapy : Silencing intracellular negative immune regulators of dendritic cells. / Liu, Yao Hua; Yeh, I. Jeng; Lai, Ming-Derg; Liu, Kuan Ting; Kuo, Po Lin; Yen, Meng Chi.

In: Cancers, Vol. 11, No. 1, 108, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cancer immunotherapy

T2 - Silencing intracellular negative immune regulators of dendritic cells

AU - Liu, Yao Hua

AU - Yeh, I. Jeng

AU - Lai, Ming-Derg

AU - Liu, Kuan Ting

AU - Kuo, Po Lin

AU - Yen, Meng Chi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be a strategy to silence specific intracellular targets in DCs. This review provides an overview of the known negative immune regulators of DCs. Moreover, a combination of shRNA/siRNA and DC vaccines, DNA vaccines in animal models, and clinical trials are also discussed.

AB - Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be a strategy to silence specific intracellular targets in DCs. This review provides an overview of the known negative immune regulators of DCs. Moreover, a combination of shRNA/siRNA and DC vaccines, DNA vaccines in animal models, and clinical trials are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=85061980750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061980750&partnerID=8YFLogxK

U2 - 10.3390/cancers11010108

DO - 10.3390/cancers11010108

M3 - Review article

AN - SCOPUS:85061980750

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 108

ER -